Wobble Genomics

Executive Summary

Wobble Genomics is a UK-based biotechnology company pioneering a novel approach to cancer detection through full-length RNA sequencing from blood samples. Founded in 2020 and headquartered in Edinburgh, the company aims to identify previously undetectable biomarkers that could fundamentally transform cancer diagnostics and monitoring. By analyzing complete RNA transcripts rather than short fragments, Wobble's technology captures the full complexity of gene expression and splicing events, potentially enabling earlier and more accurate detection of malignancies. The company operates in the rapidly evolving field of liquid biopsy, seeking to offer a non-invasive alternative to traditional tissue biopsies while providing richer molecular information. Despite being at an early stage with no disclosed funding rounds or valuation, Wobble Genomics has entered a competitive space alongside other RNA-based diagnostics players, but its focus on full-length sequencing distinguishes it from fragment-based approaches.

Upcoming Catalysts (preview)

• Q2 2026Completion of pilot clinical study demonstrating proof-of-concept in at least one cancer type60% success
• Q4 2026Announcement of Series A funding round led by prominent health-tech venture capital50% success
• Q1 2027Strategic partnership with a pharmaceutical company for co-development of RNA-based companion diagnostics30% success